QIBA PET-Amyloid Biomarker Committee (BC) Call
10 August 2018 at 9:00 AM CT

Call Summary

Some additional notes added by Ms. Matthews

In attendance:

Dawn Matthews, MS, MBA (Co-Chair)
Rachid Fahmi, MSc, PhD
Jean-Luc Vanderheyden, PhD
Joe Koudelik
Satoshi Minoshima, MD, PhD (Co-Chair)
Nancy Obuchowski, PhD
Richard Wahl, MD, FACR
Julie Lisiecki
Anne Smith, PhD (Co-Chair)
Eric Perlman, MD
Xiaoyou Ying, PhD
Tammie Benzinger, MD, PhD

RSNA

Moderator:  Ms. Matthews

Technical Feasibility Process

• The Amyloid Profile was approved for publishing as Consensus (Stage #2) by the Amyloid BC and NM CC
  o Public comment has been addressed
• The next step is to create a site feasibility questionnaire for use in clinical applications or clinical trials
  o A questionnaire will be created based on the normative Profile text to gain site feedback in order to
    create a practical site checklist
  o Real world site input is needed to make the checklist efficient as well as to inform the Profile regarding
    what may need to be revised to improve it
• The questionnaire will ask respondents to select from the following:
  o Currently in practice; Feasible; Feasible, but not going to implement
  o Based upon discussion during the call, the “Feasible” category may be more representative than the
    “Currently in practice”, because sites may implement certain practices according to the relevant
    protocol, which may vary depending upon the intended use.

Potential list of volunteer Technically Confirmed Sites:

• UT Southwestern (Dr. Subramaniam)
• Wash U (Dr. Wahl)
• 2-3 high-power academic sites needed to start, with the hope to expand to an additional 7 centers (for a total
  of 10) that may represent the broader community
• Dr. Minoshima suggested that some sites from those that provided comments on the Profile could be
  approached for this effort (these sites have already demonstrated a willingness to review the content that
  would be included in the questionnaire)

Regarding the spreadsheet:

• Suggestion that the volunteer sites fill in columns F & G, similarly to what was done for the FDG Profile
  o Group discussion that filling in columns F & G is not necessary – column E would be clear enough; it is
    desirable to reduce any unnecessary or redundant time spent on re-phrasing requirements
• It was suggested that web/telephone interviews of sites might allow for faster and more efficient feedback
• Europe may be doing more clinical Amyloid scanning due to different reimbursement criteria
• Dr. Smith will evaluate the spreadsheet on behalf of Siemens PET/CT products re: vendor conformance
• Ms. Matthews will review the spreadsheet for any intended changes per public comment that may have not
  been included in all relevant boxes of the edited version (one example is the inclusion of “qualified personnel”
  in administration of a radiotracer)
• Version control is important to make sure that the latest version is being used
**Nuclear Medicine WebEx Schedule:**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/07</td>
<td>FDG-PET BC</td>
</tr>
<tr>
<td>09/11</td>
<td>TC $^{99m}$ Tc BC @ 2pm CT</td>
</tr>
<tr>
<td>09/14</td>
<td>PET Amyloid BC</td>
</tr>
<tr>
<td>09/21</td>
<td>I-123 BC - TBD</td>
</tr>
<tr>
<td>09/28</td>
<td>NM Coordinating Committee</td>
</tr>
</tbody>
</table>